Uterine sarcoma

What changed: Uterine sarcoma

Cancer page →

Every dated change on the records linked to Uterine sarcoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-10This recordUterine sarcoma
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 1

2022MilestoneDoxorubicin
LMS-04: doxorubicin plus trabectedin improves progression-free survival
Pautier and colleagues, Lancet Oncol.

2018 · 1

2018MilestoneGemcitabine
GOG-0277 closed early
Adjuvant chemotherapy for stage I LMS did not improve outcomes; observation is standard.

2017 · 1

2017MilestoneDoxorubicin
GeDDiS: gemcitabine-docetaxel not superior to doxorubicin
Seddon and colleagues, Lancet Oncol; doxorubicin retained as first line.

2014 · 1

2014MilestoneUterine sarcoma
FDA warns against power morcellation
Unsuspected uterine sarcoma disseminated by morcellation during fibroid surgery.

2012 · 1

2012MilestoneUterine sarcoma
JAZF1-SUZ12 and YWHAE-NUTM2 fusions define low- and high-grade ESS
Lee and colleagues; earlier Koontz 2001 for JAZF1.

2008 · 1

2008MilestoneUterine sarcoma
EORTC 55874: adjuvant pelvic radiotherapy does not improve survival in uterine sarcoma
A milestone in how this cancer is treated.